DarioHealth ( (DRIO) ) has released its Q1 earnings. Here is a breakdown of the information DarioHealth presented to its investors.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
DarioHealth Corp. is a global digital therapeutics company that provides personalized, evidence-based interventions for managing chronic conditions through precision data analytics, software, and coaching. In its latest earnings report for the first quarter of 2025, DarioHealth reported a net loss of $9.2 million, an increase from the previous year’s loss of $7.2 million, despite a revenue increase to $6.75 million from $5.76 million. The company’s gross profit improved to $3.88 million, driven by growth in its business-to-business-to-consumer (B2B2C) segment, but operating expenses remained high at $13.3 million. DarioHealth’s financial strategy includes managing its cash flow and leveraging its credit facilities, with a focus on achieving profitability through product development and market expansion. The management remains optimistic about future growth, emphasizing the importance of strategic partnerships and innovation in digital health solutions.